Amneal Pharmaceuticals, Inc. AMRX
Amneal Pharmaceuticals, Inc. (the "Company", "we," "us," or "our") is a diversified, global biopharmaceutical company that develops, manufactures, markets, and distributes a diverse portfolio of essential medicines. Our Affordable Medicines segment includes retail generics, injectables, and biosimilars. In our Specialty segment, we offer a portfolio of branded pharmaceuticals focused primarily on central nervous system and endocrine disorders. Through our AvKARE segment, we are a distributor of pharmaceuticals and other products for the U.S. federal government, retail, and institutional markets. We operate principally in the United States ("U.S."), India, and Ireland. Refer to the section "Segments of the Business" below for an overview of our segments.
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $3.02B | $2.79B | $2.39B | $2.21B | $2.09B | $1.99B | $1.63B | $1.66B | $1.03B | $1.02B |
| Cost of revenue | $1.91B | $1.77B | $1.57B | $1.43B | $1.32B | $1.33B | $1.15B | $938.8M | $507.5M | $420.8M |
| Gross profit | $1.11B | $1.02B | $820.6M | $784.7M | $769.0M | $628.4M | $353.0M | $716.4M | $526.2M | $597.5M |
| R&D | $186.2M | $190.7M | $163.9M | $195.7M | $201.8M | $179.9M | $188.0M | $194.2M | $171.4M | $179.0M |
| SG&A | $526.8M | $476.4M | $429.7M | $399.7M | $365.5M | $326.7M | $289.6M | $227.8M | $109.0M | $118.8M |
| Operating income | $394.1M | $249.3M | $204.4M | -$94.9M | $152.7M | $91.2M | -$248.7M | -$19.7M | $245.1M | $284.9M |
| Pre-tax income | $139.2M | -$55.0M | -$40.3M | -$248.1M | $31.4M | -$35.8M | -$220.2M | -$202.7M | $171.3M | $214.8M |
| Income tax | $11.3M | $18.9M | $8.5M | $6.7M | $11.2M | $104.4M | $383.3M | $1.4M | $2.0M | $5.4M |
| Net income | $72.1M | -$116.9M | -$84.0M | -$254.8M | $13.2M | $67.8M | -$603.6M | -$19.7M | $0 | $0 |
| EPS, basic | 0.23 | -0.38 | -0.48 | -0.86 | 0.07 | 0.62 | -2.74 | -0.16 | — | — |
| EPS, diluted | 0.22 | -0.38 | -0.48 | -0.86 | 0.07 | 0.61 | -2.74 | -0.16 | — | — |
| Shares, diluted (wtd. avg.) | $324.8M | $309.0M | $176.1M | $150.9M | $151.8M | $148.9M | $132.1M | $127.3M | — | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $282.0M | $110.6M | $91.5M | $35.2M | $256.7M | $347.1M | $152.8M | $218.8M | $77.9M | $37.5M |
| Receivables | — | — | — | $741.8M | $662.6M | $638.9M | $604.4M | $481.5M | $351.4M | — |
| Inventory | $606.3M | $612.5M | $581.4M | $530.7M | $489.4M | $490.6M | $381.1M | $457.2M | $284.0M | — |
| Total current assets | $1.91B | $1.59B | $1.38B | $1.41B | $1.52B | $1.55B | $1.21B | $1.29B | $771.9M | — |
| Property, plant and equipment | $442.9M | $424.9M | $447.6M | $469.8M | $514.2M | $477.8M | $478.0M | $544.1M | $486.8M | — |
| Goodwill | $595.5M | $597.4M | $598.6M | $598.9M | $593.0M | $522.8M | $419.5M | $426.2M | $26.4M | $28.4M |
| Other intangibles | $563.5M | $732.4M | $890.4M | $1.10B | $1.17B | $1.30B | $1.38B | $1.65B | $44.6M | — |
| Total assets | $3.68B | $3.50B | $3.47B | $3.80B | $3.94B | $4.01B | $3.67B | $4.35B | $1.34B | — |
| Accounts payable | — | — | — | $166.0M | $131.1M | $153.1M | $103.0M | $114.8M | $70.0M | — |
| Short-term debt | $6.8M | $224.2M | $34.1M | $30.0M | $30.6M | $44.2M | $21.5M | $21.4M | $89.2M | — |
| Total current liabilities | $881.6M | $1.13B | $846.6M | $752.8M | $677.2M | $676.9M | $550.4M | $553.9M | $296.9M | — |
| Long-term debt | $2.57B | $2.16B | $2.39B | $2.59B | $2.68B | $2.74B | $2.61B | $2.63B | $1.36B | — |
| Total liabilities | — | — | — | — | — | — | — | — | $0 | — |
| Retained earnings | -$535.0M | -$607.1M | -$490.2M | -$406.2M | -$276.2M | -$286.8M | -$377.9M | -$20.9M | -$382.8M | — |
| Total equity | -$70.8M | -$109.3M | $20.0M | $184.0M | $367.0M | $344.9M | $346.8M | $896.4M | $0 | — |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $340.0M | $295.1M | $345.6M | $65.1M | $241.8M | $379.0M | $1.7M | $250.2M | $234.2M | $115.1M |
| Depreciation and amortisation | $57.3M | $62.6M | $66.2M | $68.1M | $60.7M | $60.4M | $63.3M | $64.4M | $42.0M | $29.3M |
| Stock-based compensation | $32.0M | $27.8M | $26.8M | $31.8M | $28.4M | $20.8M | $21.7M | $167.6M | $0 | $0 |
| Capital expenditure | $70.1M | $51.9M | $43.2M | $46.4M | $47.7M | $56.4M | $47.2M | $83.1M | $94.8M | $122.8M |
| Investing cash flow | -$112.3M | -$63.0M | -$69.2M | -$174.3M | -$194.2M | -$317.5M | -$19.6M | -$396.4M | -$98.6M | -$124.6M |
| Financing cash flow | -$31.5M | -$211.8M | -$212.6M | -$106.6M | -$138.1M | $131.8M | -$45.8M | $287.7M | -$95.0M | -$19.5M |
| Dividends paid | — | — | — | — | — | $0 | $0 | $183.0M | $375.3M | $200.6M |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001723128-26-000011.
Others in SIC 2834
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| AKTX | Akari Therapeutics Plc | $1.79T | — | — |
| LLY | ELI LILLY & Co | $1.08T | 50.1x | 44.7% |
| JNJ | JOHNSON & JOHNSON | $663.28B | 25.0x | 6.0% |
| ONC | BeOne Medicines Ltd. | $529.55B | 1,885.6x | 40.2% |
| ABBV | AbbVie Inc. | $453.19B | 108.7x | 8.6% |
| MRK | Merck & Co., Inc. | $370.89B | 20.6x | 1.3% |
| ABT | ABBOTT LABORATORIES | $188.69B | 29.1x | 5.7% |
| PFE | PFIZER INC | $162.16B | 20.9x | -1.6% |